Caroline Murphy
Research Subjects
Research Interests
Caroline Murphy has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Hui Ma
School of Biotechnology, , Dublin, Ireland
3 shared publicationsJenny Fitzgerald
School of Chemical Sciences, , Dublin, Ireland
3 shared publicationsAoife Crawley
School of Biotechnology, , Dublin, Ireland
2 shared publicationsEdwina Stack
School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
2 shared publicationsFiona Regan
School of Chemical Sciences DCU Water Institute, Dublin City University Dublin Ireland
2 shared publicationsRichard O'Kennedy
School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland; Hamad Bin Khalifa University and Research, Development and Innovation, Qatar Foundation, Doha, Qatar
2 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Wiley in Environmental DNA
- Vol. 8 (2)
Development of a European Sea Bass eDNA Assay for Remote Ocean Observation
The European Sea Bass ( Dicentrarchus labrax ) is a commercially and recreationally significant species across European waters. Despite its value, wild populations have suffered due to overfishing and environmental change, increasing reliance on aquaculture and heightening the need for effective conservation tools. This study reports the first development of a species‐specific environmental DNA (eDNA) assay for D. labrax using recombinase polymerase amplification (RPA) coupled with CRISPR‐Cas detection. The assay is designed for autonomous sensing applications and is both highly sensitive (limit of detection: < 1 pg) and specific, showing no cross‐reactivity with closely related species (as assessed on a qPCR instrument) such as sea bream and other species likely to be found in its marine environment. To optimize field deployment, we validated the assay on lyophilized reagents preserved with trehalose, enabling storage and function on polymethyl methacrylate (PMMA) microfluidic platforms. We further demonstrated successful integration of the assay onto a Lab‐on‐Chip (LOC) system, with simplified fluidics allowing the full RPA reaction volume to rehydrate CRISPR reagents, eliminating the need for intermediate handling. The assay maintained performance when tested with both tissue‐extracted and environmental DNA, including samples from the Wexford Estuary, Ireland. Fluorescence‐based detection on a portable fluorometer was achieved through extended incubation times and reagent optimization. The results confirm that this RPA‐CRISPR‐Cas assay is suitable for non‐laboratory settings that will support real‐time, in situ monitoring of European sea bass populations. This work represents a significant step toward scalable, autonomous eDNA monitoring solutions for marine biodiversity and fisheries management.
- 1 March 2026
- Published by Wiley in Environmental DNA
- Vol. 8 (2)
Open AccessDevelopment of a European Sea Bass eDNA Assay for Remote Ocean Observation
The European Sea Bass ( Dicentrarchus labrax ) is a commercially and recreationally significant species across European waters. Despite its value, wild populations have suffered due to overfishing and environmental change, increasing reliance on aquaculture and heightening the need for effective conservation tools. This study reports the first development of a species‐specific environmental DNA (eDNA) assay for D. labrax using recombinase polymerase amplification (RPA) coupled with CRISPR‐Cas detection. The assay is designed for autonomous sensing applications and is both highly sensitive (limit of detection: < 1 pg) and specific, showing no cross‐reactivity with closely related species (as assessed on a qPCR instrument) such as sea bream and other species likely to be found in its marine environment. To optimize field deployment, we validated the assay on lyophilized reagents preserved with trehalose, enabling storage and function on polymethyl methacrylate (PMMA) microfluidic platforms. We further demonstrated successful integration of the assay onto a Lab‐on‐Chip (LOC) system, with simplified fluidics allowing the full RPA reaction volume to rehydrate CRISPR reagents, eliminating the need for intermediate handling. The assay maintained performance when tested with both tissue‐extracted and environmental DNA, including samples from the Wexford Estuary, Ireland. Fluorescence‐based detection on a portable fluorometer was achieved through extended incubation times and reagent optimization. The results confirm that this RPA‐CRISPR‐Cas assay is suitable for non‐laboratory settings that will support real‐time, in situ monitoring of European sea bass populations. This work represents a significant step toward scalable, autonomous eDNA monitoring solutions for marine biodiversity and fisheries management.
- Open Access
- 9 February 2024
- Published by Frontiers Media SA in Frontiers in Sensors
- Vol. 5, 1302520
Evaluation of a point-of-use device used for autoantibody analysis and its potential for following microcystin leucine-arginine exposure
Introduction: Globally, the need for measuring exposure to algal toxins has become urgent due to ever-increasing reports of contamination in sea and freshwater, in shellfish and fish stocks and in aerosols.Methods: To address this issue, we evaluated the potential of determining autoantibodies to a panel of biomarkers known to be elevated following exposure to the hepatotoxin microcystin leucine-arginine. The presence of autoantibodies, specific to four selected stress-response, metabolomic and chaperone biomarkers, namely, Heat shock protein 1, Triosephosphate isomerase, Peroxiredoxin 1 and Peroxiredoxin 2 was employed in screening 371 serum samples from microcystin-exposed individuals in Tanzania. In addition, the capacity of the LightDeck fluorescence-based detector, a point-of-use device, to monitor these autoantibody responses in comparison to enzyme-linked immunosorbent assay was evaluated.Results: By using the determination of autoantibodies to this novel panel of biomarkers an altered response was observed following microcystin exposure, with levels generally upregulated. The presence of elevated levels of microcystin leucine-arginine in water, as well as in food sources in Tanzania, may potentially have significant health effects on the population.Discussion: This novel biomarker panel may have potential for the detection of microcystin leucine-arginine exposure as well as various microcystin exposure-associated cancers (e.g., hepatocellular cancer and colorectal cancer). In addition, the utilisation of the LightDeck point-of-use device proved successful for the rapid analysis of this biomarker panel.
- 9 February 2024
- Published by Frontiers Media SA in Frontiers in Sensors
- Vol. 5, 1302520
Open AccessEvaluation of a point-of-use device used for autoantibody analysis and its potential for following microcystin leucine-arginine exposure
Introduction: Globally, the need for measuring exposure to algal toxins has become urgent due to ever-increasing reports of contamination in sea and freshwater, in shellfish and fish stocks and in aerosols.Methods: To address this issue, we evaluated the potential of determining autoantibodies to a panel of biomarkers known to be elevated following exposure to the hepatotoxin microcystin leucine-arginine. The presence of autoantibodies, specific to four selected stress-response, metabolomic and chaperone biomarkers, namely, Heat shock protein 1, Triosephosphate isomerase, Peroxiredoxin 1 and Peroxiredoxin 2 was employed in screening 371 serum samples from microcystin-exposed individuals in Tanzania. In addition, the capacity of the LightDeck fluorescence-based detector, a point-of-use device, to monitor these autoantibody responses in comparison to enzyme-linked immunosorbent assay was evaluated.Results: By using the determination of autoantibodies to this novel panel of biomarkers an altered response was observed following microcystin exposure, with levels generally upregulated. The presence of elevated levels of microcystin leucine-arginine in water, as well as in food sources in Tanzania, may potentially have significant health effects on the population.Discussion: This novel biomarker panel may have potential for the detection of microcystin leucine-arginine exposure as well as various microcystin exposure-associated cancers (e.g., hepatocellular cancer and colorectal cancer). In addition, the utilisation of the LightDeck point-of-use device proved successful for the rapid analysis of this biomarker panel.
- 29 January 2023
- Published by Springer Nature
- p. 47-61
Antibody, Aptamer and Affimer-Based Affinity Tools for Marine Toxin Biosensing
- 29 January 2023
- Published by Springer Nature
- p. 47-61
Antibody, Aptamer and Affimer-Based Affinity Tools for Marine Toxin Biosensing
- 31 December 2019
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 32 (12) , 533-542
Understanding microcystin-LR antibody binding interactions using in silico docking and in vitro mutagenesis
Microcystins (MCs) are a group of highly potent cyanotoxins that are becoming more widely distributed due to increased global temperatures and climate change. Microcystin-leucine-arginine (MC-LR) is the most potent and most common variant, with a guideline limit of 1 μg/l in drinking water. We previously developed a novel avian single-chain fragment variable (scFv), designated 2G1, for use in an optical-planar waveguide detection system for microcystin determination. This current work investigates interactions between 2G1 and MC-LR at the molecular level through modelling with an avian antibody template and molecular docking by AutoDock Vina to identify key amino acid (AA) residues involved. These potential AA interactions were investigated in vitro by targeted mutagenesis, specifically, by alanine scanning mutations. Glutamic acid (E) was found to play a critical role in the 2G1-MC-LR binding interaction, with the heavy chain glutamic acid (E) 102 (H-E102) forming direct bonds with the arginine (R) residue of MC-LR. In addition, alanine mutation of light chain residue aspartic acid 57 (L-D57) led to an improvement in antigen-binding observed using enzyme-linked immunosorbent assay (ELISA), and was confirmed by surface plasmon resonance (SPR). This work will contribute to improving the binding of recombinant anti-MC-LR to its antigen and aid in the development of a higher sensitivity harmful algal toxin diagnostic.
- 31 December 2019
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 32 (12) , 533-542
Understanding microcystin-LR antibody binding interactions using in silico docking and in vitro mutagenesis
Microcystins (MCs) are a group of highly potent cyanotoxins that are becoming more widely distributed due to increased global temperatures and climate change. Microcystin-leucine-arginine (MC-LR) is the most potent and most common variant, with a guideline limit of 1 μg/l in drinking water. We previously developed a novel avian single-chain fragment variable (scFv), designated 2G1, for use in an optical-planar waveguide detection system for microcystin determination. This current work investigates interactions between 2G1 and MC-LR at the molecular level through modelling with an avian antibody template and molecular docking by AutoDock Vina to identify key amino acid (AA) residues involved. These potential AA interactions were investigated in vitro by targeted mutagenesis, specifically, by alanine scanning mutations. Glutamic acid (E) was found to play a critical role in the 2G1-MC-LR binding interaction, with the heavy chain glutamic acid (E) 102 (H-E102) forming direct bonds with the arginine (R) residue of MC-LR. In addition, alanine mutation of light chain residue aspartic acid 57 (L-D57) led to an improvement in antigen-binding observed using enzyme-linked immunosorbent assay (ELISA), and was confirmed by surface plasmon resonance (SPR). This work will contribute to improving the binding of recombinant anti-MC-LR to its antigen and aid in the development of a higher sensitivity harmful algal toxin diagnostic.
- 1 December 2018
- Published by Elsevier in Journal of Immunological Methods
- Vol. 463, 127-133
Enhancing recombinant antibody performance by optimally engineering its format
- 1 December 2018
- Published by Elsevier in Journal of Immunological Methods
- Vol. 463, 127-133
Enhancing recombinant antibody performance by optimally engineering its format
- Open Access
- 2 June 2018
- Published by MDPI AG in Diagnostics
- Vol. 8 (2) , 39
Developments in Point-of-Care Diagnostic Technology for Cancer Detection
Cancer is the cause of death for one in seven individuals worldwide. It is widely acknowledged that screening and early diagnosis are of vital importance for improving the likelihood of recovery. However, given the costly, time-consuming, and invasive nature of the many methods currently in use, patients often do not take advantage of the services available to them. Consequently, many researchers are exploring the possibility of developing fast, reliable, and non-invasive diagnostic tools that can be used directly or by local physicians at the point-of-care. Herein, we look at the use of established biomarkers in cancer therapy and investigate emerging biomarkers exhibiting future potential. The incorporation of these biomarkers into point-of-care devices could potentially reduce the strain currently experienced by screening programs in hospitals and healthcare systems. Results derived from point-of-care tests should be accurate, sensitive, and generated rapidly to assist in the selection of the best course of treatment for optimal patient care. Essentially, point-of-care diagnostics should enhance the well-being of patients and lead to a reduction in cancer-related deaths.
- 2 June 2018
- Published by MDPI AG in Diagnostics
- Vol. 8 (2) , 39
Open AccessDevelopments in Point-of-Care Diagnostic Technology for Cancer Detection
Cancer is the cause of death for one in seven individuals worldwide. It is widely acknowledged that screening and early diagnosis are of vital importance for improving the likelihood of recovery. However, given the costly, time-consuming, and invasive nature of the many methods currently in use, patients often do not take advantage of the services available to them. Consequently, many researchers are exploring the possibility of developing fast, reliable, and non-invasive diagnostic tools that can be used directly or by local physicians at the point-of-care. Herein, we look at the use of established biomarkers in cancer therapy and investigate emerging biomarkers exhibiting future potential. The incorporation of these biomarkers into point-of-care devices could potentially reduce the strain currently experienced by screening programs in hospitals and healthcare systems. Results derived from point-of-care tests should be accurate, sensitive, and generated rapidly to assist in the selection of the best course of treatment for optimal patient care. Essentially, point-of-care diagnostics should enhance the well-being of patients and lead to a reduction in cancer-related deaths.
- Open Access
- 1 April 2017
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 89, 53-59
Don't blame it all on antibodies – The need for exhaustive characterisation, appropriate handling, and addressing the issues that affect specificity
- 1 April 2017
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 89, 53-59
Open AccessDon't blame it all on antibodies – The need for exhaustive characterisation, appropriate handling, and addressing the issues that affect specificity
- Open Access
- 1 February 2017
- Published by Taylor & Francis in Advanced Health Care Technologies
- Vol. ume 3, 1-2
Technology advancements in antibody purification [Corrigendum]
Technology advancements in antibody purification [Corrigendum] Murphy C, Devine T, Oâ
- 1 February 2017
- Published by Taylor & Francis in Advanced Health Care Technologies
- Vol. ume 3, 1-2
Open AccessTechnology advancements in antibody purification [Corrigendum]
Technology advancements in antibody purification [Corrigendum] Murphy C, Devine T, Oâ
- 1 May 2015
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 67, 708-714
Detection of the cyanobacterial toxin, microcystin-LR, using a novel recombinant antibody-based optical-planar waveguide platform
- 1 May 2015
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 67, 708-714
Detection of the cyanobacterial toxin, microcystin-LR, using a novel recombinant antibody-based optical-planar waveguide platform